Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Furthermore, components of Wnt signaling, namely, Wnt3a and GSK-3β, interlink MetS and AD. 31325024 2020
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE Malathion exposure induced spatial learning and memory deficits with a simultaneous decrease of PSD93 and TAU hyperphosphorylation at multiple AD-related phosphorylation sites with activation of glycogen synthase kinase-3β (GSK-3β) and inhibition of protein phosphatase-2A (PP2A). 30789100 2020
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE Our findings further support that increased kinase activity of GSK3β is associated with AD pathology in the PFC. 29804228 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE Mechanistically, VPA treatment increased β-catenin levels, accumulated the inactive form of glycogen synthase kinase-3β (GSK-3β), and induced the expression of NeuroD1, a Wnt target gene involved in neurogenesis, suggesting the activation of the Wnt signaling pathway in the hippocampus of 3xTgAD mice. 30971911 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE However, whether the inhibition of the activation of mTOR via the regulation of the function of GSK3β affects the pathology of AD remains unclear. 31115485 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 GeneticVariation disease BEFREE Herein, we highlight nine major targets associated with AD, which are acetylcholine esterase (AChE), beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype of histamine receptor (H<sub>3</sub> receptor), and phosphodiesterases (PDEs), and their respective relationship to the disease network. 31103902 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE In this sense, here we report the rational design of a multi-target directed ligand (MTDL) for AD based on virtual screening and bioinformatic analyses, exploring the molecular targets β-secretase (BACE-1), glycogen synthase kinase-3β (GSK-3β) and acetylcholinesterase (AChE). 31086208 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE The quinolin-2-one derivative ZINC67773573 was found to be a promising lead for designing new GSK-3β inhibitors for Alzheimer's disease treatment. 31129879 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 GeneticVariation disease BEFREE This work aims to provide a novel tool for early diagnosis and pathological mechanism exploration about AD by detecting inchoate change of GSK-3β content in body fluid, thus to precaution the risk of Alzheimer's disease. 31322849 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Leptin may be protective against the development of AD as it can inactivate GSK-3β through the phosphorylation of Ser-9, leading to the reduction of tau phosphorylation. 30954605 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Arylbenzofurans from the Root Bark of <i>Morus alba</i> as Triple Inhibitors of Cholinesterase, β-Site Amyloid Precursor Protein Cleaving Enzyme 1, and Glycogen Synthase Kinase-3β: Relevance to Alzheimer's Disease. 31459768 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE Taken together, our findings suggest that GRK5 deficiency contributes to the pathogenesis of Alzheimer's disease by influencing the hyperphosphorylation of tau through the activation of GSK3β. 30511419 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE It has demonstrated that glycogen synthase kinase 3β (GSK3β) is related to Alzheimer's disease (AD). 30888812 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Therefore, compound 9b might be a good lead for the development of novel GSK-3β inhibitors targeting multi-facets of AD. 30772605 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Glycogen synthase kinase 3β (GSK-3β) is a widely investigated molecular target for numerous diseases including Alzheimer's disease, cancer, and diabetes mellitus. 30902399 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE This study is the first to demonstrate a transient increase in phosphor-Tau caused by PKA, but not GSK3β, in the CSF and induced pluripotent stem cells (iPSCs) of AD, implying that both GSKIP and GSK3β function as anchoring proteins to strengthen the cAMP/PKA/Tau axis signaling during AD pathogenesis. 31640277 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Thus, bergenin was screened by molecular docking study using GOLD suite (version 5.2), CCDC for predicting its activity against targets of AD management like acetylcholinesterase (AChE) (1B41), butyrylcholinesterase (BuChE) (1P0I), Tau protein kinase 1 (GSK-3β) (1J1B), BACE-1 (1FKN) wherein the GOLD score and fitness of bergenin were comparable to those of standard drugs like donepezil, galanthamine, physostigmine, etc. 30118774 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE BACE-1 and GSK-3β both are potential therapeutic drug targets for Alzheimer's disease. 29310523 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE In conclusion, GSPs ameliorate neuronal oxidative damage and cognitive impairment by inhibiting GSK-3β-dependent mPTP opening in AD. 31232699 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 AlteredExpression disease BEFREE Results showed that co-administration of CA to d-gal/AlCl<sub>3</sub> induced AD-like rat models significantly increased the levels of protein phosphatase 2 (PP2A) and decreased the levels of glycogen synthase kinase-3 beta (GSK-3β). 31014012 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Glycogen synthase kinase 3β (GSK3β), a serine/threonine protein kinase, is involved in several human diseases, including type II diabetes, mood disorders, prostate cancer, and Alzheimer's disease, representing a potential therapeutic target. 30949773 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Our findings indicate that the upregulation of TTBK1 and GSK-3β mediated by the loss of miR-219-5p is a possible mechanism that contributes to tau phosphorylation and AD progression. 30556160 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE Based on the reported connection among histone deacetylases (HDACs) and glycogen synthase kinase 3β (GSK-3β), herein we present the discovery and the biochemical characterization of the first-in-class hit compound able to exert promising anti-AD effects by modulating the targeted proteins in the low micromolar range of concentration. 30996781 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 Biomarker disease BEFREE IL-2 and GSK3B proteins are T and natural killer (NK) cell regulators and have previously been associated with other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple system atrophy. 31123295 2019
Entrez Id: 2932
Gene Symbol: GSK3B
GSK3B
0.700 GeneticVariation disease BEFREE Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity. 29944335 2019